MCID: THY125
MIFTS: 52

Thyroid Gland Medullary Carcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Thyroid Gland Medullary Carcinoma

MalaCards integrated aliases for Thyroid Gland Medullary Carcinoma:

Name: Thyroid Gland Medullary Carcinoma 12
Medullary Thyroid Carcinoma 12 15
Medullary Carcinoma of the Thyroid Gland 12
Ultimobranchial Thyroid Tumour 12
Ultimobranchial Thyroid Tumor 12
Thyroid Medullary Carcinoma 15
Thyroid Cancer, Medullary 44

Classifications:



External Ids:

Disease Ontology 12 DOID:3973
MeSH 44 C536914
NCIt 50 C3879
SNOMED-CT 68 32913002
UMLS 72 C0238462

Summaries for Thyroid Gland Medullary Carcinoma

Disease Ontology : 12 A thyroid gland carcinoma that has material basis in parafollicular cells.

MalaCards based summary : Thyroid Gland Medullary Carcinoma, also known as medullary thyroid carcinoma, is related to multiple endocrine neoplasia, type iib and thyroiditis. An important gene associated with Thyroid Gland Medullary Carcinoma is MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1), and among its related pathways/superpathways are Peptide ligand-binding receptors and Signaling by GPCR. The drugs Tyrosine and Liraglutide have been mentioned in the context of this disorder. Affiliated tissues include thyroid, testes and lymph node, and related phenotypes are growth/size/body region and endocrine/exocrine gland

Related Diseases for Thyroid Gland Medullary Carcinoma

Diseases related to Thyroid Gland Medullary Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 322)
# Related Disease Score Top Affiliating Genes
1 multiple endocrine neoplasia, type iib 32.6 RET MEN1 GDNF CALCA
2 thyroiditis 31.5 TG RET CALCA
3 papillary carcinoma 31.4 TG RET CALCA
4 nodular goiter 31.3 TG RET CALCA
5 paraganglioma 31.3 SST RET CHGA
6 hyperparathyroidism 31.2 RET MEN1 CHGA CALCA
7 hashimoto thyroiditis 31.0 TG RET CALCA
8 malignant pheochromocytoma 30.9 SST CHGA CALCA
9 differentiated thyroid carcinoma 30.8 TG RET NTRK1
10 duodenal somatostatinoma 30.8 SST CALCA
11 neuroma 30.8 RET GDNF CALCA
12 follicular adenoma 30.7 TG RET CALCA
13 primary hyperparathyroidism 30.7 RET MEN1 CHGA CALCA
14 neuroendocrine tumor 30.7 SSTR2 SST MEN1 CHGA CALCA
15 parathyroid adenoma 30.7 RET MEN1 CHGA CALCA
16 fetal adenoma 30.6 TG CALCA
17 somatostatinoma 30.5 SST CHGA CALCA
18 mucoepidermoid carcinoma 30.4 TG CHGA CALCA
19 carcinoid tumors, intestinal 30.2 SSTR2 SST MEN1 CHGA
20 laurence-moon syndrome 30.2 RET POMC
21 hypothyroidism 30.2 TG RET POMC CALCA
22 parathyroid gland disease 30.2 RET MEN1 CALCA
23 parathyroid carcinoma 30.2 RET MEN1 CALCA
24 ganglioneuroma 30.1 RET NTRK1 CHGA
25 von hippel-lindau syndrome 30.1 RET MEN1 CHGA
26 insulinoma 30.0 SST MEN1 CHGA
27 multiple endocrine neoplasia, type i 30.0 SST RET MEN1 CHGA
28 meningioma, familial 30.0 SSTR2 SST MEN1
29 thyroid gland disease 29.8 TG SST RET POMC CALCA
30 endocrine gland cancer 29.8 TG SST RET MEN1 CHGA CALCA
31 conn's syndrome 29.7 SST POMC MEN1
32 constipation 29.7 SST RET GDNF CALCA
33 spinal meningioma 29.7 TG CHGA
34 adenoma 29.7 SSTR5 SST RET POMC MEN1
35 multiple endocrine neoplasia, type iia 29.5 RET MEN1 GDNF CALCA
36 multiple endocrine neoplasia 29.5 RET MEN1 GDNF CHGA CALCA
37 pituitary tumors 29.2 SSTR5 SST POMC MEN1
38 small cell cancer of the lung 28.8 SSTR2 SST POMC MALAT1 CHGA CALCA
39 thyroid cancer, nonmedullary, 2 27.2 TG SSTR2 SST RET POMC MEN1
40 pheochromocytoma 26.4 SSTR1 SST RET POMC NTRK1 MEN1
41 thyroid carcinoma, familial medullary 26.3 TG SSTR5 SSTR2 SSTR1 SST RET
42 thyroid cancer, nonmedullary, 1 11.9
43 thyroid carcinoma 11.5
44 goiter 10.7
45 wdha syndrome 10.7 SST CALCA
46 thyroid gland papillary carcinoma 10.7
47 thyroid carcinoma, hurthle cell 10.7 TG MALAT1
48 suppurative thyroiditis 10.6 TG CALCA
49 thyroid sarcoma 10.6 TG CALCA
50 ovarian germ cell teratoma 10.6 TG RET

Graphical network of the top 20 diseases related to Thyroid Gland Medullary Carcinoma:



Diseases related to Thyroid Gland Medullary Carcinoma

Symptoms & Phenotypes for Thyroid Gland Medullary Carcinoma

MGI Mouse Phenotypes related to Thyroid Gland Medullary Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.96 CCKBR CHGA GDNF MEN1 NTRK1 POMC
2 endocrine/exocrine gland MP:0005379 9.92 CCKBR CHGA GDNF MEN1 POMC RET
3 digestive/alimentary MP:0005381 9.91 CCKBR GDNF MEN1 RET SST SSTR2
4 homeostasis/metabolism MP:0005376 9.85 CCKBR CHGA MEN1 POMC RET SST
5 nervous system MP:0003631 9.7 CCKBR CHGA GDNF MEN1 NTRK1 POMC
6 no phenotypic analysis MP:0003012 9.1 CHGA NTRK1 POMC RET SST SSTR3

Drugs & Therapeutics for Thyroid Gland Medullary Carcinoma

Drugs for Thyroid Gland Medullary Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 116)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tyrosine Approved, Investigational, Nutraceutical Phase 4 60-18-4 6057
2
Liraglutide Approved Phase 3 204656-20-2 44147092
3
Glucagon Approved Phase 3 16941-32-5
4 Gastrointestinal Agents Phase 3
5 Hormones Phase 3
6 Hormone Antagonists Phase 3
7 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
8 Glucagon-Like Peptide 1 Phase 3
9 Incretins Phase 3
10 Hypoglycemic Agents Phase 3
11 insulin Phase 3
12 Insulin, Globin Zinc Phase 3
13
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616 46835353
14
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
15
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
16
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
17
Histamine Approved, Investigational Phase 1, Phase 2 51-45-6 774
18
Lenograstim Approved, Investigational Phase 1, Phase 2 135968-09-1
19
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
20
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
21
Tamoxifen Approved Phase 2 10540-29-1 2733526
22
Sodium citrate Approved, Investigational Phase 2 68-04-2
23
Pancrelipase Approved, Investigational Phase 2 53608-75-6
24
Melphalan Approved Phase 2 148-82-3 460612 4053
25
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
26
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
27
Pasireotide Approved Phase 2 396091-73-9 9941444
28
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
29
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
30
Iodine Approved, Investigational Phase 2 7553-56-2 807
31
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
32
Nintedanib Approved Phase 2 656247-17-5 56843413
33
Salmon Calcitonin Approved, Investigational Phase 2 47931-85-1 16129616
34
Capecitabine Approved, Investigational Phase 1, Phase 2 154361-50-9 60953
35
Dacarbazine Approved, Investigational Phase 1, Phase 2 4342-03-4 5351166
36
Bortezomib Approved, Investigational Phase 1, Phase 2 179324-69-7 93860 387447
37
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
38
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
39
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
40
Levodopa Approved Phase 2 59-92-7 6047
41
Glycine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 56-40-6 750
42
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
43
Imetelstat Investigational Phase 2 868169-64-6
44
Calcitonin gene-related peptide Investigational Phase 2 83652-28-2
45 Pancreatic Polypeptide Investigational Phase 2 59763-91-6
46 Antifungal Agents Phase 2
47 Anti-Bacterial Agents Phase 2
48 Anti-Infective Agents Phase 2
49 Antibiotics, Antitubercular Phase 2
50 Immunosuppressive Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 57)
# Name Status NCT ID Phase Drugs
1 The Use of Lu177 in the Treatment of Progressive and Unresectable Metastatic Medullary Thyroid Cancer Unknown status NCT01915485 Phase 4
2 A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients Recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
3 An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease Active, not recruiting NCT01496313 Phase 4 300mg vandetanib;150mg vandetanib
4 A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Medullary Thyroid Carcinoma(ALTER01031) Completed NCT02586350 Phase 2, Phase 3 Anlotinib;Placebo
5 Liraglutide in the Treatment of Type 1 Diabetes Mellitus Completed NCT01722266 Phase 3 Liraglutide;Placebo
6 An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer Active, not recruiting NCT00410761 Phase 3 ZD6474 (Vandetanib)
7 A Phase II Study to Investigate the Efficacy of RAD001 (Afinitor®, Everolimus) in Patients With Irresectable Recurrent or Metastatic Differentiated, Undifferentiated (Anaplastic) and Medullary Thyroid Carcinoma Unknown status NCT01118065 Phase 2 everolimus
8 A Phase I/II, Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/Day in Japanese Patients With Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma Completed NCT01661179 Phase 1, Phase 2 Vandetanib 300mg
9 Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma Completed NCT00467506 Phase 2 bispecific antibody and di-DTPA-131I
10 A Multi-center, Single-arm, Open-label Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Sorafenib in Japanese Patients With Anaplastic Thyroid Carcinoma or Locally Advanced or Metastatic Medullary Thyroid Carcinoma Completed NCT02114658 Phase 2 Sorafenib (Nexavar,BAY43-9006)
11 An Open Label, Two Stage, Phase II Study to Evaluate the Efficacy and Tolerability of ZD6474 in Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Carcinoma. Completed NCT00098345 Phase 2 ZD6474 (vandetanib)
12 Phase 2 Study of Anlotinib in Advanced Medullary Thyroid Carcinoma Completed NCT01874873 Phase 2 Anlotinib
13 An Open Label Multi-Center Phase II Study of RAD001 in Advanced Thyroid Cancer Completed NCT01164176 Phase 2 everolimus
14 A Phase II Study of ZD 1839 (IRESSA®) in Patients With Advanced Thyroid Cancer Completed NCT00095836 Phase 2 Gefitinib
15 Pharmacokinetic and Imaging Optimization Study of Pretargeted Immuno-PET Using the Anti-CEA x Anti-HSG TF2 Bispecific Antibody and 68Ga-IMP-288 Peptide in Patients With Recurrences of Medullary Thyroid Carcinoma. Completed NCT01730638 Phase 1, Phase 2 • TF2 and 68 Ga-IMP-288
16 Phase I/II Radioimmunotherapy With High-Dose 90Y-Labeled Humanized MN-14 Alone or Combined With Doxorubicin and Peripheral Blood Stem Cell Rescue (PBSCR) in Medullary Thyroid Cancer (MTC) Grant Application Title: Radioimmunotherapy of MTC With Y-90 Humanized MN14 Anti-CEA Mab and Doxorubicin Completed NCT00004048 Phase 1, Phase 2 doxorubicin hydrochloride
17 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
18 A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer Completed NCT00121628 Phase 2 AMG 706
19 A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver Completed NCT00096083 Phase 2 isolated perfusion;melphalan
20 Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma Completed NCT00887107 Phase 2 Sorafenib (nexavar)
21 Phase 2 of Sunitinib (Sutent) in Patients With Locally Advanced or Metastatic Anaplastic, Differentiated or Medullar Thyroid Cancer Completed NCT00510640 Phase 2 Sunitinib
22 Vaccine Therapy With Tumor Specific Mutated Ras Peptides and IL-2 or GM-CSF for Adult Patients With Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
23 Mono Centre, Open Label Proof of Concept Study SOM230 in Progressive Medullary Thyroid Cancer Patients and the Combination With RAD001 Upon Progression Completed NCT01625520 Phase 2 SOM230 alone or in combination with RAD001.
24 A Phase II Study of Single Agent Depsipeptide (FK228) in Radioiodine (RAI)-Refractory Metastatic Non-medullary (Papillary, Follicular, and Hurthle Cell Variants) Thyroid Carcinoma Completed NCT00098813 Phase 2 romidepsin
25 Phase II Study of Sunitinib in Iodine Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid With Functional Imaging Correlation Completed NCT00519896 Phase 2 sunitinib malate
26 Phase II Study of Capecitabine and Temozolomide for Progressive, Differentiated, Metastatic Neuroendocrine Cancers Completed NCT00869050 Phase 2 Capecitabine;Temozolomide
27 A Multi-center , Opened, Phase II Study of Safety and Efficacy of Sulfatinib in Advanced Medullary Thyroid Carcinoma ( MTC) and Iodine-refractory Differentiated Thyroid Carcinoma (DTC) Recruiting NCT02614495 Phase 2 Surufatinib
28 Phase II Study of Sorafenib (BAY 43-9006) in Patients With Metastatic Medullary Thyroid Carcinoma Active, not recruiting NCT00390325 Phase 2 Sorafenib;Sorafenib Tosylate
29 Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents With Hereditary Medullary Thyroid Carcinoma Active, not recruiting NCT00514046 Phase 1, Phase 2 Vandetanib
30 A Phase II Study Exploring the Safety and Efficacy of Nintedanib (BIBF1120) as Second Line Therapy for Patients With Either Differentiated or Medullary Thyroid Cancer Progressing After First Line Therapy. Active, not recruiting NCT01788982 Phase 2 Nintedanib;Placebo
31 Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers Active, not recruiting NCT00381641 Phase 2 Sunitinib;Sunitinib Malate
32 A Phase I/II Study to Evaluate the Efficacy and Toxicity of Imatinib Mesylate in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma Terminated NCT00354523 Phase 1, Phase 2 Capecitabine (Xeloda);DTIC-Dome (Dacarbazine);Gleevec (Imatinib Mesylate)
33 A Targeted Ph I/II Trial of ZD6474 (Vandetanib; CAPRELSA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Ca (MTC) Terminated NCT00923247 Phase 1, Phase 2 Bortezomib;Vandetanib
34 Phase II Trial of Irinotecan for Treatment of Metastatic Medullary Thyroid Cancer Terminated NCT00100828 Phase 2 irinotecan hydrochloride
35 Clinical Trial of Sir-Spheres® in Patients With Symptomatic or Progressive Hepatic Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
36 Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer. Terminated NCT00647140 Phase 2
37 Randomized Double-blind Placebo Controlled Phase II Study to Evaluate the Efficacy and Safety of Sorafenib Treatment in Patients With Advanced (Recurrent, Persistent and/or Metastasizing) Medullary Thyroid Carcinoma Withdrawn NCT01736878 Phase 2 Sorafenib
38 Phase I Clinical Trial Using a Novel CCK-2/Gastrin Receptor-localizing Radiolabelled Peptide Probe for Personalized Diagnosis and Therapy of Patients With Progressive or Metastatic Medullary Thyroid Carcinoma Unknown status NCT03246659 Phase 1 111In-CP04;111In-CP04 with co-administration of gelofusine/gelaspan
39 Phase I Trial of NGR-TNF Administered Every 3 Weeks as a 1 Hour Intravenous Infusion in Patients With Solid Tumor Completed NCT00098943 Phase 1
40 A Phase I Pharmacokinetic, Pharmacodynamic, and Clinical Study of the Combination of the Angiogenesis Inhibitor SU5416 and Paclitaxel in Recurrent or Metastatic Carcinoma of the Head and Neck Completed NCT00005647 Phase 1 paclitaxel;semaxanib
41 A Phase I Study of Active Immunotherapy With Carcinoembryonic Antigen RNA-Pulsed, Autologous Human Cultured Dendritic Cells in Patients With Metastatic Malignancies Expressing Carcinoembryonic Antigen Completed NCT00004604 Phase 1
42 A Phase I, Pharmacokinetic, and Biologic Correlative Study of R115777 (NSC 702818) and Herceptin in Patients With Advanced Cancer Completed NCT00005842 Phase 1 tipifarnib
43 B-Uptake In Different Tumours Using The Boron Compounds BSH And BPA Completed NCT00062348 Phase 1 boronophenylalanine-fructose complex;sodium borocaptate
44 177Lu-PP-F11N for Receptor Targeted Therapy and Imaging (Theranostics) of Metastatic Medullary Thyroid Cancer - a Pilot and a Phase I Study. Recruiting NCT02088645 Phase 1 177Lu-PP-F11N
45 A Phase I Study of [111In-DTPA-D-Phe]-Octreotide in Patients With Refractory Malignancies Expressing Somatostatin Receptors Terminated NCT00002947 Phase 1
46 Phase I Study of the Pharmacokinetics and Pharmacodynamics of ZD6474 in Combination With Docetaxel in Advanced Solid Tumors Withdrawn NCT00937417 Phase 1 docetaxel;vandetanib
47 Study of Molecular Pathways in Medullary Thyroid Carcinoma (MTC) and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients Completed NCT01424878
48 Impact of Tracheotomy on Levels of Serum Procalcitonin in Patients Without Sepsis: a Prospective Study Completed NCT02406079
49 177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer (Lumed Phase 0/B) Recruiting NCT03647657 Early Phase 1 177Lu-PP-F11N;Sacuitril
50 Multicenter, Prospective, Observational Study of Clinical Outcomes of Thyroid Cancer Recruiting NCT04031339

Search NIH Clinical Center for Thyroid Gland Medullary Carcinoma

Cochrane evidence based reviews: thyroid cancer, medullary

Genetic Tests for Thyroid Gland Medullary Carcinoma

Anatomical Context for Thyroid Gland Medullary Carcinoma

MalaCards organs/tissues related to Thyroid Gland Medullary Carcinoma:

41
Thyroid, Testes, Lymph Node, Bone, Liver, Lung, Breast

Publications for Thyroid Gland Medullary Carcinoma

Articles related to Thyroid Gland Medullary Carcinoma:

(show top 50) (show all 3772)
# Title Authors PMID Year
1
Identification and interaction analysis of key miRNAs in medullary thyroid carcinoma by bioinformatics analysis. 38
31322209 2019
2
Malignant teratoma of the thyroid: A difficult diagnosis by fine-needle aspiration. 38
31120625 2019
3
Establishment and characterization of a novel cell line of medullary thyroid carcinoma from a dog. 38
31144267 2019
4
Parathyroid Glands Hyperplasias Mimicking Medullary Thyroid Carcinoma Metastatic Lymph Nodes on 18F-DOPA PET/CT. 38
31274634 2019
5
Cardiac metastasis from medullary thyroid carcinoma: insights from multimodal molecular imaging and magnetic resonance imaging. 38
31397474 2019
6
Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives. 38
31252403 2019
7
Thyroid Incidentaloma on 18F-fluorocholine PET/CT and 68Ga-PSMA PET/CT Revealing a Medullary Thyroid Carcinoma. 38
31274618 2019
8
Efficacy and toxicity of sorafenib in the treatment of advanced medullary thyroid carcinoma: A systematic review and meta-analysis. 38
31162772 2019
9
Salivary and serum biomarkers of inflammation in a man with metastatic medullary thyroid carcinoma and hyperreactive gingiva: a fourteen year odyssey. 38
31423894 2019
10
Genetic risk association of CDKN1A and RET gene SNPs with medullary thyroid carcinoma: Results from the largest MTC cohort and meta-analysis. 38
31408923 2019
11
Association Between Programmed Death-Ligand 1 Expression and Clinicopathological Characteristics, Structural Recurrence, and Biochemical Recurrence/Persistent Disease in Medullary Thyroid Carcinoma. 38
31328653 2019
12
A Medullary thyroid cancer with paraganglioma-like pattern diagnosed during pregnancy: A case report and literature revision. 38
31376826 2019
13
An investigation on the expression of miRNAs including miR-144 and miR-34a in plasma samples of RET-positive and RET-negative medullar thyroid carcinoma patients. 38
31297834 2019
14
Calcitonin measurement in pediatrics: reference ranges are gender-dependent, validation in medullary thyroid cancer and thyroid diseases. 38
30794525 2019
15
Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib. 38
31118272 2019
16
RET S409Y Germline Mutation and Associated Medullary Thyroid Carcinoma. 38
31364476 2019
17
Medullary thyroid carcinoma treated with percutaneous ultrasound-guided radiofrequency ablation. 38
31273680 2019
18
[Imaging of medullary thyroid carcinoma]. 38
31367891 2019
19
Cofilin is a mediator of RET-promoted medullary thyroid carcinoma cell migration, invasion and proliferation. 38
31352037 2019
20
Retroposed copies of RET gene: a somatically acquired event in medullary thyroid carcinoma. 38
31288802 2019
21
The application value of modified thyroid imaging report and data system in diagnosing medullary thyroid carcinoma. 38
31070290 2019
22
Genetic analysis of a hereditary medullary thyroid carcinoma case with normal preoperative serum calcitonin levels. 38
31409511 2019
23
Two GEO MicroRNA Expression Profile Based High-Throughput Screen to Identify MicroRNA-31-3p Regulating Growth of Medullary Thyroid Carcinoma Cell by Targeting RASA2. 38
31298226 2019
24
[Clinical significance and cost-benefit analysis of serum calcitonin assay in diagnosis and treatment of medullary thyroid carcinoma]. 38
31315357 2019
25
The role of molecular genetics in the clinical management of sporadic medullary thyroid carcinoma: A systematic review. 38
31301229 2019
26
Clinico-pathologic and dynamic prognostic factors in sporadic and familial medullary thyroid carcinoma: an Israeli multi-center study. 38
31048559 2019
27
Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Advanced Thyroid Cancer. 38
31362663 2019
28
Ectopic ACTH Production and Cushing's Syndrome in a Patient with Parotid Acinic Cell Carcinoma with High-Grade Transformation: Tumor Context and Clinical Implications. 38
31363907 2019
29
Calcitonin concentrations in patients with chronic kidney disease on hemodialysis in reference to parathyroidectomy. 38
31324271 2019
30
DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use. 38
30530828 2019
31
Poorly differentiated thyroid carcinoma : An underdiagnosed entity. 38
31273418 2019
32
[Multiple Endocrine Neoplasia]. 38
31296813 2019
33
Authors' reply to: Absence of the MAP2K5 germline variants c.G961A and c.T1100C in a wide series of familial non-medullary thyroid carcinoma Italian families. International Journal of Cancer 2019; in press. 38
30828792 2019
34
EFFECT OF AGE AND GENDER ON FASTING AND FOOD-STIMULATED LEVELS OF CALCITONIN, PARATHYROID, AND GASTRIN HORMONES IN HEALTHY ADULTS. 38
30865531 2019
35
RET Kinase-Regulated MicroRNA-153-3p Improves Therapeutic Efficacy in Medullary Thyroid Carcinoma. 38
30929576 2019
36
Parathyroid Glands Hyperplasias Mimicking Medullary Thyroid Carcinoma Metastatic Lymph Nodes on 18F-DOPA PET/CT. 38
31162251 2019
37
Cure and survival of sporadic medullary thyroid carcinoma following systematic preoperative calcitonin screening. 38
30903267 2019
38
TTF-1 positive atypical carcinoid of the epiglottis mimicking medullary thyroid carcinoma. 38
30974468 2019
39
Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma. 38
31053251 2019
40
An unusual case of neck pains: medullary thyroid carcinoma. 38
31256052 2019
41
[Efficacy and safety of vandetanib on advanced medullary thyroid carcinoma: single center result from a phase Ⅲ study]. 38
31262109 2019
42
Expression of Prox1 in Medullary Thyroid Carcinoma Is Associated with Chromogranin A and Calcitonin Expression and with Ki67 Proliferative Index, but Not with Prognosis. 38
31001799 2019
43
The Role of Calcitonin in Predicting the Extent of Surgery in Medullary Thyroid Carcinoma: A Nationwide Population-Based Study in Norway. 38
31259158 2019
44
Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). 38
31010875 2019
45
Revisiting the Significance of Prominent C Cells in the Thyroid. 38
30694510 2019
46
Present status of prophylactic thyroidectomy in pediatric multiple endocrine neoplasia 2: a nationwide survey in Japan 1997-2017. 38
31150358 2019
47
Significance of neck dissection for the treatment of clinically-evident medullary thyroid carcinomas: A systematic review. 38
30237011 2019
48
Clear Cell Variant of a Follicular Thyroid Tumor With Uncertain Malignant Potential: A Case Report. 38
30370813 2019
49
Predictors of Response Outcomes for Research Recruitment Through a Central Cancer Registry: Evidence From 17 Recruitment Efforts for Population-Based Studies. 38
30689685 2019
50
Calcitonin negative Medullary Thyroid Carcinoma: a challenging diagnosis or a medical dilemma? 38
31142313 2019

Variations for Thyroid Gland Medullary Carcinoma

Cosmic variations for Thyroid Gland Medullary Carcinoma:

9 (show top 50) (show all 95)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM14320 VHL thyroid,NS,carcinoma,medullary carcinoma c.233A>T p.N78I 3:10142080-10142080 27
2 COSM10654 TP53 thyroid,NS,carcinoma,medullary carcinoma c.637C>T p.R213* 17:7674894-7674894 27
3 COSM6956576 SMARCA4 thyroid,NS,carcinoma,medullary carcinoma c.2120T>C p.I707T 19:11008020-11008020 27
4 COSM29805 RET thyroid,NS,carcinoma,medullary carcinoma c.1859G>C p.C620S 10:43113655-43113655 27
5 COSM965 RET thyroid,NS,carcinoma,medullary carcinoma c.2753T>C p.M918T 10:43121968-43121968 27
6 COSM5945763 RET thyroid,NS,carcinoma,medullary carcinoma c.1983C>T p.H661H 10:43114583-43114583 27
7 COSM974 RET thyroid,NS,carcinoma,medullary carcinoma c.1901G>A p.C634Y 10:43114501-43114501 27
8 COSM3437784 RET thyroid,NS,carcinoma,medullary carcinoma c.2206G>A p.G736R 10:43116653-43116653 27
9 COSM5945762 RET thyroid,NS,carcinoma,medullary carcinoma c.2249C>G p.A750G 10:43116696-43116696 27
10 COSM249791 RET thyroid,NS,carcinoma,medullary carcinoma c.1843G>A p.E615K 10:43113639-43113639 27
11 COSM964 RET thyroid,NS,carcinoma,medullary carcinoma c.1888T>C p.C630R 10:43114488-43114488 27
12 COSM918118 RET thyroid,NS,carcinoma,medullary carcinoma c.2038G>A p.A680T 10:43114638-43114638 27
13 COSM29803 RET thyroid,NS,carcinoma,medullary carcinoma c.1852T>C p.C618R 10:43113648-43113648 27
14 COSM966 RET thyroid,NS,carcinoma,medullary carcinoma c.1900T>C p.C634R 10:43114500-43114500 27
15 COSM133167 RET thyroid,NS,carcinoma,medullary carcinoma c.2647G>T p.A883S 10:43120120-43120120 27
16 COSM959 RET thyroid,NS,carcinoma,medullary carcinoma c.2627C>T p.A876V 10:43120100-43120100 27
17 COSM29807 RET thyroid,NS,carcinoma,medullary carcinoma c.1902C>T p.C634C 10:43114502-43114502 27
18 COSM249789 RET thyroid,NS,carcinoma,medullary carcinoma c.2117T>C p.V706A 10:43114717-43114717 27
19 COSM249790 RET thyroid,NS,carcinoma,medullary carcinoma c.2680G>A p.G894S 10:43120153-43120153 27
20 COSM1237918 RET thyroid,NS,carcinoma,medullary carcinoma c.1900T>A p.C634S 10:43114500-43114500 27
21 COSM6005497 RET thyroid,NS,carcinoma,medullary carcinoma c.1924G>A p.V642I 10:43114524-43114524 27
22 COSM249792 RET thyroid,NS,carcinoma,medullary carcinoma c.2041C>T p.Q681* 10:43114641-43114641 27
23 COSM960 RET thyroid,NS,carcinoma,medullary carcinoma c.2650G>A p.E884K 10:43120123-43120123 27
24 COSM5945770 RET thyroid,NS,carcinoma,medullary carcinoma c.2733T>G p.G911G 10:43121948-43121948 27
25 COSM963 RET thyroid,NS,carcinoma,medullary carcinoma c.2701G>A p.E901K 10:43120174-43120174 27
26 COSM5945755 RET thyroid,NS,carcinoma,medullary carcinoma c.2771T>C p.F924S 10:43121986-43121986 27
27 COSM21338 RET thyroid,NS,carcinoma,medullary carcinoma c.2304G>C p.E768D 10:43118392-43118392 27
28 COSM5598719 RET thyroid,NS,carcinoma,medullary carcinoma c.2137G>A p.E713K 10:43116584-43116584 27
29 COSM975 RET thyroid,NS,carcinoma,medullary carcinoma c.1902C>G p.C634W 10:43114502-43114502 27
30 COSM5945761 RET thyroid,NS,carcinoma,medullary carcinoma c.2256C>T p.Y752Y 10:43116703-43116703 27
31 COSM29804 RET thyroid,NS,carcinoma,medullary carcinoma c.1858T>C p.C620R 10:43113654-43113654 27
32 COSM961 RET thyroid,NS,carcinoma,medullary carcinoma c.2723G>A p.R908K 10:43120196-43120196 27
33 COSM978 RET thyroid,NS,carcinoma,medullary carcinoma c.1892A>G p.D631G 10:43114492-43114492 27
34 COSM4170226 RET thyroid,NS,carcinoma,medullary carcinoma c.1946C>T p.S649L 10:43114546-43114546 27
35 COSM971 RET thyroid,NS,carcinoma,medullary carcinoma c.2296C>T p.P766S 10:43118384-43118384 27
36 COSM29806 RET thyroid,NS,carcinoma,medullary carcinoma c.1888T>G p.C630G 10:43114488-43114488 27
37 COSM20889 RET thyroid,NS,carcinoma,medullary carcinoma c.2761G>A p.E921K 10:43121976-43121976 27
38 COSM6005498 RET thyroid,NS,carcinoma,medullary carcinoma c.1886T>A p.L629Q 10:43114486-43114486 27
39 COSM970 RET thyroid,NS,carcinoma,medullary carcinoma c.2756C>T p.A919V 10:43121971-43121971 27
40 COSM5945757 RET thyroid,NS,carcinoma,medullary carcinoma c.2180G>A p.G727E 10:43116627-43116627 27
41 COSM5945758 RET thyroid,NS,carcinoma,medullary carcinoma c.1804A>G p.I602V 10:43113600-43113600 27
42 COSM958 RET thyroid,NS,carcinoma,medullary carcinoma c.2242G>T p.G748C 10:43116689-43116689 27
43 COSM5946160 RET thyroid,NS,carcinoma,medullary carcinoma c.1858T>A p.C620S 10:43113654-43113654 27
44 COSM20888 RET thyroid,NS,carcinoma,medullary carcinoma c.2732G>A p.G911D 10:43121947-43121947 27
45 COSM980 RET thyroid,NS,carcinoma,medullary carcinoma c.1853G>A p.C618Y 10:43113649-43113649 27
46 COSM5945760 RET thyroid,NS,carcinoma,medullary carcinoma c.2752A>C p.M918L 10:43121967-43121967 27
47 COSM583 NRAS thyroid,NS,carcinoma,medullary carcinoma c.182A>T p.Q61L 1:114713908-114713908 27
48 COSM584 NRAS thyroid,NS,carcinoma,medullary carcinoma c.182A>G p.Q61R 1:114713908-114713908 27
49 COSM6968164 MGA thyroid,NS,carcinoma,medullary carcinoma c.1228G>T p.E410* 15:41696238-41696238 27
50 COSM1237679 MDC1 thyroid,NS,carcinoma,medullary carcinoma c.6266C>A p.T2089N 6:30700469-30700469 27

Expression for Thyroid Gland Medullary Carcinoma

Search GEO for disease gene expression data for Thyroid Gland Medullary Carcinoma.

Pathways for Thyroid Gland Medullary Carcinoma

GO Terms for Thyroid Gland Medullary Carcinoma

Cellular components related to Thyroid Gland Medullary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.43 SSTR5 SSTR3 SSTR2 SSTR1 RET NTRK1
2 neuronal cell body GO:0043025 8.8 SST RET NTRK1

Biological processes related to Thyroid Gland Medullary Carcinoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.92 SSTR5 SSTR3 SSTR2 SSTR1 SST POMC
2 cell-cell signaling GO:0007267 9.83 SSTR3 SST POMC CALCA
3 forebrain development GO:0030900 9.71 SSTR3 SSTR2 SSTR1
4 negative regulation of cell proliferation GO:0008285 9.7 SSTR5 SSTR3 SSTR2 SSTR1 SST NTRK1
5 regulation of blood pressure GO:0008217 9.69 POMC CHGA CALCA
6 cerebellum development GO:0021549 9.65 SSTR3 SSTR2 SSTR1
7 response to starvation GO:0042594 9.63 SSTR3 SSTR2 SSTR1
8 cellular response to estradiol stimulus GO:0071392 9.61 SSTR3 SSTR2 SSTR1
9 innervation GO:0060384 9.59 RET NTRK1
10 sympathetic nervous system development GO:0048485 9.58 NTRK1 GDNF
11 cellular response to glucocorticoid stimulus GO:0071385 9.58 SSTR5 SSTR3 SSTR2
12 enteric nervous system development GO:0048484 9.56 RET GDNF
13 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.56 SSTR5 SSTR3 SSTR2 SSTR1
14 peristalsis GO:0030432 9.55 SSTR2 GDNF
15 hormone-mediated apoptotic signaling pathway GO:0008628 9.49 SSTR3 SST
16 neuropeptide signaling pathway GO:0007218 9.35 SSTR5 SSTR3 SSTR2 SSTR1 POMC
17 response to pain GO:0048265 9.28 RET
18 detection of temperature stimulus involved in sensory perception of pain GO:0050965 9.27 NTRK1
19 somatostatin signaling pathway GO:0038170 8.92 SSTR5 SSTR3 SSTR2 SSTR1
20 signal transduction GO:0007165 10.02 TG SSTR5 SSTR3 SSTR2 SSTR1 RET

Molecular functions related to Thyroid Gland Medullary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.65 SSTR5 SSTR3 SSTR2 SSTR1 CCKBR
2 signaling receptor binding GO:0005102 9.62 SSTR3 POMC GDNF CALCA
3 hormone activity GO:0005179 9.46 TG SST POMC CALCA
4 neuropeptide binding GO:0042923 9.26 SSTR5 SSTR3 SSTR2 SSTR1
5 somatostatin receptor activity GO:0004994 8.92 SSTR5 SSTR3 SSTR2 SSTR1

Sources for Thyroid Gland Medullary Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....